(Q38192967)

30 August 2017

1 reference

title

Role of lithium augmentation in the management of major depressive disorder (English)

1 reference

30 August 2017

5

Maximilian Pilhatsch

1 reference

30 August 2017

2

Mazda Adli

1 reference

30 August 2017

1

Michael Bauer

1 reference

30 August 2017

Roland Ricken

3

1 reference

30 August 2017

Emanuel Severus

series ordinal

4

1 reference

30 August 2017

publication date

1 April 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

28

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

331-342

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-014-0152-8

30 August 2017

exact match

0 references

cites work

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Augmentation strategies for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Is successful lithium augmentation limited to serotonergic antidepressants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

The double-blind, randomized, placebo-controlled trial: gold standard or golden calf?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

A comparison of electroconvulsive therapy with a combined lithium and tricyclic combination among depressed tricyclic nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Discontinuation of lithium augmentation in an elderly cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Predicting outcome of lithium added to antidepressants in resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Predictors of efficacy in lithium augmentation for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium toxicity profile: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Using ultrasonography to determine thyroid size and prevalence of goiter in lithium-treated patients with affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium modulates tryptophan hydroxylase 2 gene expression and serotonin release in primary cultures of serotonergic raphe neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Potential mechanisms of action of lithium in bipolar disorder. Current understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

BDNF release from single cells elicits local dendritic growth in nearby neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Brain-derived neurotrophic factor and neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Excellent lithium responders have normal cognitive functions and plasma BDNF levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Serotonin transporter gene and response to lithium augmentation in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Hyperactivity and enhanced curiosity of mice expressing PKB/SGK-resistant glycogen synthase kinase-3 (GSK-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Greater cortical gray matter density in lithium-treated patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Three-dimensional mapping of hippocampal anatomy in unmedicated and lithium-treated patients with bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Increased gray matter volume in lithium-treated bipolar disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Evidence for association of anACCN1gene variant with response to lithium treatment in Sardinian patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Is the safety of lithium no longer in the balance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0152-8

Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease.

21 January 2018

1 reference

12 December 2020

Inhibition of GSK3 by lithium, from single molecules to signaling networks

1 reference

12 December 2020

A haplotype-based study of lithium responding patients with bipolar affective disorder on the Faroe Islands

1 reference

12 December 2020

Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response

1 reference

12 December 2020

Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression

1 reference

12 December 2020

Discontinuation of lithium augmentation in geriatric patients with unipolar depression: a systematic review

1 reference

12 December 2020

The benefit of lithium carbonate adjunct in refractory depression--fact or fiction?

1 reference

12 December 2020

Commentary on a recent review of lithium toxicity: what are its implications for clinical practice?

1 reference

12 December 2020

Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association

1 reference

12 December 2020

Study of the association of serotonin transporter triallelic 5-HTTLPR and STin2 VNTR polymorphisms with lithium prophylaxis response in bipolar disorder

1 reference

12 December 2020

Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants

1 reference

12 December 2020

Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study

1 reference

12 December 2020

Effects of lithium on the hypothalamo-pituitary-adrenal axis

1 reference

12 December 2020

Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study.

1 reference

12 December 2020

Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study

1 reference

12 December 2020

Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression

1 reference

12 December 2020

Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.

1 reference

12 December 2020

Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: an open-label study

1 reference

12 December 2020

Increased extracellular serotonin level in rat hippocampus induced by chronic citalopram is augmented by subchronic lithium: neurochemical and behavioural studies in the rat.

1 reference

12 December 2020

Lithium as an adjunct in the treatment of major depression.

1 reference

12 December 2020

A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation

1 reference

12 December 2020

Chronic lithium chloride injection increases glucocorticoid receptor but not mineralocorticoid receptor mRNA expression in rat brain

1 reference

12 December 2020

Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial

1 reference

12 December 2020

Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis

1 reference

12 December 2020

Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium

1 reference

12 December 2020

A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression

1 reference

12 December 2020

The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness

1 reference

12 December 2020

Addition of lithium to chronic antidepressant treatment potentiates presynaptic serotonergic function without changes in serotonergic receptors in the rat cerebral cortex

1 reference

12 December 2020

10.1007/S40263-014-0152-8

Identifiers

DOI

1 reference

30 August 2017

1 reference